Feb 01, 2018

Organizational and Personnel Changes

TOKYO, February 1, 2018 - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today the following organizational changes, effective April 1, 2018, and personnel changes, effective March 22, 2018 and April 1, 2018.

【Details of Organizational Changes】

Effective April 1, 2018

  • Establishment of organization to promote personalized healthcare (PHC)

PHC Strategy Dept. will be newly established in the Project & Lifecycle Management Unit as an organization responsible for planning and executing strategies for the realization of PHC, including cancer genome medicine, while also enhancing the organization to promote PHC2.0 (Personalized Healthcare 2.0) developed by the Roche Group.

Functions of PHC Strategy Dept.

  1. Domestic commercialization and product value maximization of Foundation Medicine Inc.’s (FMI) “Comprehensive Genomic Profiling Service”
  2. Enhancement of R&D activities through the sophistication and planning of mid to long-term PHC and biomarker strategies, centered around genomic medicine, toward the further realization of PHC
  • Structural and functional reorganization related to clinical development
  1. Integration of clinical study management functions
    In order to conduct all clinical studies in compliance with GCP* according to the global standard of quality and speed, clinical study management functions currently in the Translational Clinical Research (TCR), Clinical Development (CD), and Medical Affairs (MA) divisions, will be integrated into the Clinical Study Management Dept. in CD Div. With this integration, TCR Study Management Dept. will be abolished, and TCR Operation Dept. will be integrated into TCR Science & Strategy Dept. Functions for clinical study planning will remain within the respective divisions (TCR Div., CD Div. and MA Div.).
  2. Establishment of Clinical Information & Intelligence Dept. in CD Div.
    In order to respond to the considerable changes in the business environment, Clinical Information & Intelligence Dept. will be newly established in the CD Div. to work as a hub for all data collection, management, analysis and transmissions regarding clinical development activities to strengthen data utilization and intelligence functions, which enable the planning of optimal clinical development strategies.
  3. Establishment of Clinical Pharmacology Dept. in TCR Div.
    The importance of clinical pharmacology functions in the research and development of pharmaceutical products is increasing, and with the recognition that the clinical pharmacology function requires further enhancement in order to maintain the competitive advantage of the Company, Clinical Pharmacology Dept. will be newly established in the TCR Div. to enhance the cooperation with the respective divisions, including the Research Div. which accelerate early acquisition of PoC**.

*: Good Clinical Practice (Standard practice for conducting clinical studies of pharmaceutical products)

**: Proof of Concept (Demonstration that the therapeutic effects conceived in the research stage is effective in clinical setting)

<Image of clinical development after integration of clinical study management functions>
In the planning stages, the respective divisions will design clinical studies according to the missions of the respective organizations. Clinical Development Management Dept. will be responsible for conducting all of the GCP compatible clinical studies designed by the respective companies and divisions.

【Details of Personnel Changes】

Effective March 22, 2018

Director

NameNew ResponsibilityCurrent Responsibility
Yoshio Itaya Full-time Senior Advisor Director, Executive Vice President and CFO
General Manager of Finance Supervisory Div.
In charge of IT Supervisory Div.

Vice President

NameNew ResponsibilityCurrent Responsibility
Toshiaki Itagaki Vice President and CFO
General Manager of Finance Supervisory Div., General Manager of IT Supervisory Div. and General Manager of Finance & Accounting Dept.
Vice President
General Manager of IT Supervisory Div. and General Manager of Finance & Accounting Dept.

Effective April 1, 2018

  • Implementation of Executive Vice President System
    The company will implement a new governance system with Executive Vice Presidents (“Executive Vice President system”) where their supervisory responsibilities for divisions and functions are clearly divided and defined, aiming to speed up and enhance quality of decision-making and business operations.
    Executive Vice President will be a member of the Executive Committee.

Directors

NameNew ResponsibilitiesCurrent Responsibilities
Motoo Ueno Representative Director, Deputy Chairman
Executive Officer in charge of Corporate Social Responsibility, Risk Management, Compliance and Audit
Representative Director, Deputy Chairman
Corporate Social Responsibility Dept., Audit Dept.
Tatsuro Kosaka Representative Director, CEO
Executive Officer in charge of Pharmaceutical Technology, Marketing & Sales and External Affairs
Representative Director, CEO

Vice Presidents

NameNew ResponsibilitiesCurrent Responsibilities
Shinya Unno Executive Vice President
In charge of Human Resources Management, Human Capital Development, Legal, General Affairs, and Secretarial
And General Manager of Human Resources Supervisory Div.
Senior Vice President
General Manager of Human Resources Supervisory Div.
General Affairs, Secretarial
Yasushi Ito Executive Vice President
In charge of Project & Lifecycle Management (R&D), Regulatory & Quality Management, Clinical Development, Drug Safety and Medical Affairs
And Co-Head of Project & Lifecycle Management Unit
Senior Vice President
Head of Project & Lifecycle Management Unit
In charge of Regulatory & Quality Management, Clinical Development, Drug Safety, Medical Affairs
Osamu Okuda Executive Vice President
In charge of Project & Lifecycle Management (Marketing) and Corporate Planning
And Co-Head of Project & Lifecycle Management Unit
Senior Vice President
General Manager of Corporate Planning Dept.
Hisafumi Okabe Executive Vice President
In charge of Research and Translational Clinical Research
And General Manager of Translational Clinical Research Div.
Senior Vice President
In charge of Research, Translational Clinical Research
Toshiaki Itagaki Executive Vice President and CFO
In charge of Finance & Accounting, Corporate Communication, Information System and Purchasing
And General Manager of Finance Supervisory Div., General Manager of IT Supervisory Div. and General Manager of Finance & Accounting Dept.
Vice President
General Manager of IT Supervisory Div.
General Manager of Finance & Accounting Dept.
Susumu Kato Senior Vice President
Special Mission for CEO
Senior Vice President
General Manager of Marketing & Sales Div.
Yoshiaki Ohashi Senior Vice President
Head of Quality & Regulatory Compliance Unit and General Manager of Drug Safety Div.
Vice President
Head of Quality & Regulatory Compliance Unit and General Manager of Drug Safety Div.
Toshihiko Komori Vice President
In charge of Intellectual Property Dept., Project & Lifecycle Management Unit
Vice President
General Manager of Translational Clinical Research Div.
Hiroshi Murata Vice President
General Manager of Pharmaceutical Technology Div.
Associate Vice President
General Manager of Pharmaceutical Technology Div.
Shinji Hidaka Vice President
General Manager of Medical Affairs Div.
Vice President
Deputy General Manager of Marketing & Sales Div.(Marketing & Sales Promotion)
Tsunanori Sato Vice President
General Manager of Marketing & Sales Div.
Associate Vice President
Head of Kansai Regional Management Office, Marketing & Sales Div.
Hiroyuki Matsumoto Vice President
Head of Kanto-Minami Regional Management Office, Marketing & Sales Div.
Associate Vice President
Deputy General Manager of Marketing & Sales Div. (Marketing & Sales Planning, Customer Relationship Management, Wholesaler Business Planning) and Department Manager of Wholesaler Business Planning Dept., Marketing & Sales Div.
Minoru Watanabe Vice President
General Manager of Corporate Planning Dept.
Associate Vice President
General Manager of Research Div.

Please see the PDF file about other personnel changes.

Contact:

  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Koki Harada
  • Tel: +81-3-3273-0881
  • E-mail: pr@chugai-pharm.co.jp
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Toshiya Sasai
  • Tel: +81-3-3273-0554
  • E-mail: ir@chugai-pharm.co.jp
  • Like
  • Tweet
  • LINE it!
  • E-mail
Back to top